US EditionPublished • loading... • Updated
AbbVie to Build $1.4 Billion Manufacturing Campus in North Carolina
The campus will add 734 jobs and more than 2,000 construction positions as AbbVie expands production of medicines worldwide.
- On Wednesday, AbbVie announced a $1.4 billion investment to build a 185-acre pharmaceutical manufacturing campus in Durham, North Carolina, marking the company's largest-ever capital investment in a single campus.
- The project aligns with AbbVie's $100 billion commitment to U.S. research and capital investments; officials selected Durham for its strong local workforce and capacity to support future expansion.
- AbbVie plans to hire 734 people over four years, including engineers and scientists, while development will generate more than 2,000 construction jobs supporting immunology, neuroscience, and oncology medicines.
- City of Durham Mayor Leonardo Williams called it "the largest private investment in the history of our city," while Governor Josh Stein praised the state as a premier biopharmaceutical location.
- Construction begins this year, with completion expected by the end of 2028, when the campus will serve as a center of excellence for small volume parenteral manufacturing worldwide.
Insights by Ground AI
21 Articles
21 Articles
·Washington, United States
Read Full Article
JDIG funds pharmaceutical manufacturer in Durham
One of the world’s largest biopharmaceutical manufacturers, AbbVie Inc., headquartered in Illinois, is coming to North Carolina, announced Gov. Josh Stein on April 22, and will invest $1.4 billion to build a 185-acre manufacturing campus in Durham, promising to create 734 jobs. “We welcome AbbVie’s major investment to North Carolina,” said Stein, in a press release. “When you combine our world-renowned research and innovation with a strong, thr…
Coverage Details
Total News Sources21
Leaning Left4Leaning Right3Center4Last UpdatedBias Distribution37% Left, 36% Center
Bias Distribution
- 37% of the sources lean Left, 36% of the sources are Center
37% Left
L 37%
C 36%
R 27%
Factuality
To view factuality data please Upgrade to Premium
